Abstract
Primary gastric lymphoma accounts for about 2% of gastric neoplasms. The prognosis of patients affected with non-Hodgkin's gastric lymphoma appear better than for other lymphatic sites. In a retrospective study, the authors have analyzed 45 patients, by evaluating the histopathologic characteristics and relative prognostic factors. The main factors significantly influencing 5-yr survival are: serosal penetration (31.17% vs. 71.2%, P <0.05), regional lymph node involvement (53.07% vs. 68%), and clinical stage of disease (IE: 85.6%, IVE:10%, P <0.001). The histologic characteistics, the high or low grade of malignancy, and patient age can also be considered important prognostic factors, but not statistically significant in our series of cases. Comparison between overall survival and disease-free survival of patients in stages IE and IIE who underwent surgery alone, with those who had chemotherapy and/or radiotherapy after surgery shows a higher survival (85.6%) of the group who had combined treatments, even though this difference is not statistically significant.
| Original language | English |
|---|---|
| Pages (from-to) | 1461-1465 |
| Number of pages | 5 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 22 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 1986 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Primary gastric lymphoma : A review of 45 cases. / Ravaioli, A.; Amadori, M.; Faedi, M.; Rosti, G.; Folli, S.; Barbieri, C.; Giorgini, G.; Marangolo, M.; Emiliani, E.; Amadori, D.
In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 12, 1986, p. 1461-1465.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Primary gastric lymphoma
T2 - A review of 45 cases
AU - Ravaioli, A.
AU - Amadori, M.
AU - Faedi, M.
AU - Rosti, G.
AU - Folli, S.
AU - Barbieri, C.
AU - Giorgini, G.
AU - Marangolo, M.
AU - Emiliani, E.
AU - Amadori, D.
PY - 1986
Y1 - 1986
N2 - Primary gastric lymphoma accounts for about 2% of gastric neoplasms. The prognosis of patients affected with non-Hodgkin's gastric lymphoma appear better than for other lymphatic sites. In a retrospective study, the authors have analyzed 45 patients, by evaluating the histopathologic characteristics and relative prognostic factors. The main factors significantly influencing 5-yr survival are: serosal penetration (31.17% vs. 71.2%, P <0.05), regional lymph node involvement (53.07% vs. 68%), and clinical stage of disease (IE: 85.6%, IVE:10%, P <0.001). The histologic characteistics, the high or low grade of malignancy, and patient age can also be considered important prognostic factors, but not statistically significant in our series of cases. Comparison between overall survival and disease-free survival of patients in stages IE and IIE who underwent surgery alone, with those who had chemotherapy and/or radiotherapy after surgery shows a higher survival (85.6%) of the group who had combined treatments, even though this difference is not statistically significant.
AB - Primary gastric lymphoma accounts for about 2% of gastric neoplasms. The prognosis of patients affected with non-Hodgkin's gastric lymphoma appear better than for other lymphatic sites. In a retrospective study, the authors have analyzed 45 patients, by evaluating the histopathologic characteristics and relative prognostic factors. The main factors significantly influencing 5-yr survival are: serosal penetration (31.17% vs. 71.2%, P <0.05), regional lymph node involvement (53.07% vs. 68%), and clinical stage of disease (IE: 85.6%, IVE:10%, P <0.001). The histologic characteistics, the high or low grade of malignancy, and patient age can also be considered important prognostic factors, but not statistically significant in our series of cases. Comparison between overall survival and disease-free survival of patients in stages IE and IIE who underwent surgery alone, with those who had chemotherapy and/or radiotherapy after surgery shows a higher survival (85.6%) of the group who had combined treatments, even though this difference is not statistically significant.
UR - http://www.scopus.com/inward/record.url?scp=0022893096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022893096&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(86)90080-5
DO - 10.1016/0277-5379(86)90080-5
M3 - Article
VL - 22
SP - 1461
EP - 1465
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 12
ER -